VERV

Verve Therapeutics, Inc. · NASDAQ

Performance

-12.44%

1W

-47.3%

1M

-41.58%

3M

-38.06%

6M

-45.48%

YTD

-44.49%

1Y

Profile

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Investment Analysis Report: VERV

Overview

VERV is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has shown significant growth in its financial metrics over the past three years, with a market capitalization of $1.028 billion. In this report, we will analyze VERV's financial health, ea...

See more ...

Technical Analysis of VERV 2024-04-12

Overview:

In analyzing the technical indicators for VERV over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential invest...

See more ...

Recent News & Updates